PLK1 and cancer: In 2007, Santamaria et al. described the innovation and application of zk-thiazolidinone (TAL) 161 as a potent small-molecule inhibitor of mammalian polo-like kinase 1 (Plk1) which is a significant mitotic progression regulator and cell division and has been well thought out as a probable target for cancer treatment.